stockportfolio.pro
Innoviva, Inc. (INVA)
Healthcare · Biotechnology · NasdaqGS
Innoviva, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $133.57M | $217.22M | $261.00M | $261.02M | $336.79M | $391.87M | $331.34M | $310.46M | $358.71M | $411.33M |
| Gross profit | — | — | — | — | — | — | — | $246.04M | $296.21M | $307.67M |
| Net income | $59.54M | $134.27M | $406.33M | $190.99M | $293.81M | $368.84M | $220.26M | $179.72M | $23.39M | $271.17M |
| Net margin | 44.6% | 61.8% | 155.7% | 73.2% | 87.2% | 94.1% | 66.5% | 57.9% | 6.5% | 65.9% |
Source: Innoviva, Inc. SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of Innoviva, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track INVA in your portfolio →
About Innoviva, Inc.
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Innoviva, Inc. — frequently asked questions
What is Innoviva, Inc.'s revenue?
Innoviva, Inc. (INVA) reported revenue of $411.33M for fiscal year 2025, up 14.7% from the prior year, according to its SEC filings.
Is Innoviva, Inc. profitable?
Yes. INVA earned net income of $271.17M in fiscal 2025, a net margin of 65.9%.
What is INVA's P/E ratio?
Innoviva, Inc. trades at a price-to-earnings ratio of about 3.7 based on the latest data in our nightly-refreshed cache.
How fast is Innoviva, Inc. growing?
INVA's revenue grew at roughly 4.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Innoviva, Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.